The Week Ahead: Fed...
Health Care: Drugs
Exact Sciences Corporation (EXAS: NASDAQ)
$9.55 -0.10 | -1.04%
06/04/12 - 12:25 PM ET
Company Balance Sheet
| Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | |
| Assets | ||||
|---|---|---|---|---|
| Cash and Equivalents | 35.78M | 78.75M | 21.92M | 4.94M |
| Receivables | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 0.00 | 0.00 | 500.00K | 0.00 |
| Total Current Assets | 94.40M | 95.66M | 25.31M | 5.13M |
| Property, Plant & Equipment, Gross | 3.35M | 1.24M | 614.00K | 187.00K |
| Accumulated Depreciation & Depletion | 796.00K | 386.00K | 156.00K | 111.00K |
| Property, Plant & Equipment, Net | 2.56M | 854.00K | 458.00K | 76.00K |
| Intangibles | 0.00 | 0.00 | 0.00 | 95.00K |
| Other Non-Current Assets | 0.00 | 0.00 | 0.00 | 600.00K |
| Total Non-Current Assets | 2.56M | 854.00K | 458.00K | 771.00K |
| Liabilities & Shareholder Equity | ||||
| Total Assets | 96.95M | 96.52M | 25.77M | 5.90M |
| Accounts Payable | 765.00K | 1.03M | 155.00K | 683.00K |
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Liabilities | 0.00 | 0.00 | 0.00 | 1.50M |
| Total Current Liabilities | 7.98M | 7.16M | 6.53M | 5.03M |
| Long Term Debt | 1.00M | 1.00M | 1.00M | 0.00 |
| Deferred Income Taxes | 0.00 | 0.00 | 11.16M | 1.35M |
| Other Non-Current Liabilities | 4.48M | 8.60M | 989.00K | 1.95M |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Non-Current Liabilities | 5.48M | 9.60M | 13.15M | 3.30M |
| Total Liabilities | 13.46M | 16.76M | 19.68M | 8.33M |
| Preferred Stock Equity | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Stock Equity | 83.50M | 79.75M | 6.09M | -2.43M |
| Common Par | 566.00K | 522.00K | 355.00K | 275.00K |
| Additional Paid In Capital | 304.77M | 272.38M | 187.33M | 169.85M |
| Cumulative Translation Adjustment | 0.00 | 0.00 | 0.00 | 0.00 |
| Retained Earnings | -221.82M | -193.15M | -181.59M | -172.46M |
| Treasury Stock | 0.00 | 0.00 | 0.00 | -97.00K |
| Other Equity Adjustments | -14.00K | 1.00K | -1.00K | 0.00 |
| Total Capitalization | 84.50M | 80.75M | 7.09M | -2.43M |
| Total Equity | 83.50M | 79.75M | 6.09M | -2.43M |
| Total Liabilities & Stock Equity | 96.95M | 96.52M | 25.77M | 5.90M |
| Total Common Shares Outstanding | 56.62M | 52.16M | 35.52M | 30.76M |
| Preferred Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Treasury Shares | 0.00 | 0.00 | 0.00 | 86.00K |
| Basic Weighted Shares Outstanding | 52.51M | 40.46M | 32.79M | 27.21M |
| Diluted Weighted Shares Outstanding | 52.51M | 40.46M | 32.79M | 27.21M |
| Number of Employees | 61 | 35 | 19 | 4 |
| Number of Part-Time Employees | 0 | 0 | 0 | 0 |
Portfolios with EXAS
- Portfolio NameUser Type
- Contributor22 Biopharma Stocks With Br...
- Contributor8 Health Care Stocks With R...
- Usergdean1
- Userradforj John's SEP & Ta...
- UserBlind Rookie
- Userbbrads Portfolio 1
- Userremodelit Portfolio 1
- UserGoBears Under $5 Stock Picks
- UserMornan
- Userjwpao Portfolio 1
Latest EXAS Headlines from TheStreet
- 22 Biopharma Stocks With Breakout Potential in 2012 05.22.12 | 08:05 am
- Look to Exact Sciences, Not Radient Pharma, for Best Colon Cancer Screen Test 01.23.12 | 01:01 pm
- Biotech Stock Mailbag: YM Bio, Exact, Peregrine 12.09.11 | 06:12 am
- Exact Sciences Corporation (EXAS): CORRECTION 10.06.11 | 04:10 pm
- Exact Sciences' Colon Cancer Screening Trial 07.12.11 | 08:07 am
- 8 Health Care Stocks With Recent Gains 06.29.11 | 02:06 pm
- Biotech Stock Mailbag: Neoprobe 05.06.11 | 07:05 am
- Radient Pharma Readies Onko-Sure Data 03.29.11 | 02:03 pm
- Mayo Clinic Denies Test Link to Radient Pharma 03.07.11 | 05:03 pm
- Biotech Stock Mailbag: Exact Sciences 02.25.11 | 07:02 am
Press Releases for EXAS
- Exact Sciences To Participate In June Investor Conferences - Business Wire 05.30.12 | 10:05 am
- Exact Sciences Extends, Expands Relationship With Mayo Clinic - Business Wire 05.17.12 | 09:05 am
- Exact Sciences To Participate In May Investor Conferences - Business Wire 05.07.12 | 11:05 am
- Exact Sciences Reports First-Quarter 2012 Financial Results - Business Wire 05.01.12 | 07:05 am
- Exact Sciences To Host First-Quarter 2012 Results Webcast And Call - Business Wire 04.23.12 | 02:04 pm
- Exact Sciences’ Executives, Colon Cancer Challenge Leaders To Ring Nasdaq Opening Bell - Business Wire 03.19.12 | 09:03 am
- Exact Sciences To Participate In March Investor Conferences - Business Wire 02.29.12 | 11:02 am
- Exact Sciences Reports Fourth-Quarter, Full-Year 2011 Financial Results - Business Wire 02.23.12 | 07:02 am
- Exact Sciences Announces Appointment Of Stoltenberg As Chief Commercial Officer - Business Wire 02.20.12 | 04:02 pm
- Exact Sciences Promotes Arora To Chief Operating Officer - Business Wire 02.16.12 | 04:02 pm
Partner Headlines for EXAS
- UPDATE: Auriga Raises PT to $13 on EXACT Sciences - Benzinga 02.24.12 | 04:02 pm
- Exact Sciences Promotes Arora to Chief Operating Officer - Benzinga 02.16.12 | 04:02 pm
- 10 Undervalued Biotech Stocks With Insider Buying - Seeking Alpha 06.23.11 | 06:06 am
- Momentum Ideas: Friday's High Volume Gainers Chased by Big Money Managers - Seeking Alpha 04.17.11 | 07:04 am
- Cramer's Mad Money - 6 Earnings and IPOs to Watch for the Coming Week (4/8/11) - Seeking Alpha 04.10.11 | 04:04 am
- Life Science Portfolios: Reflecting on a Year of Out-Performance - Seeking Alpha 12.29.10 | 05:12 am
- UPDATE1-New colon cancer test works without colonoscopy - Reuters 10.28.10 | 05:10 pm
- Detecting More Upside Potential for EXACT Sciences - Seeking Alpha 10.22.10 | 09:10 pm
- Piper Jaffray’s Top Picks for The Second Half of 2010 (CPHD, EXAS, GNMK) - Benzinga 08.24.10 | 09:08 am
- 6 Ways to Trade FDA and Clinical Trial News - Seeking Alpha 05.28.10 | 02:05 pm
